中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2015年
9期
79-81
,共3页
孟鲁司特钠%糖皮质激素%哮喘
孟魯司特鈉%糖皮質激素%哮喘
맹로사특납%당피질격소%효천
Montelukast sodium%Glucocorticoid%Asthma
目的：探讨孟鲁司特钠联合糖皮质激素在中老年哮喘患者中的治疗效果。方法对本院就诊的80例中老年哮喘患者，根据不同治疗方法分为两组，对照组给予常规基础治疗及吸入糖皮质激素治疗，实验组在对照组基础上联合孟鲁司特钠治疗，比较两组治疗效果。结果实验组95%患者的治疗效果肯定，高于对照组（80%）（P ＜0.05）；实验组治疗后 FEV1指标为（2.22±0.18）L、PEF 指标为（4.89±0.48）L、FEV1/FVC指标为（88.54±5.62）%，高于对照组 FEV1指标为（1.45±0.29）L、PEF 指标为（3.51±0.47）L、FEV1/FVC指标为（77.13±6.43）%，（P ＜0.05）；实验组喘息缓解时间为（5.3±0.6）d，咳嗽缓解时间为（6.5±0.8）d、胸闷缓解时间为（5.8±0.7）d，短于对照组喘息缓解时间为（7.8±0.3）d，咳嗽缓解时间为（8.6±0.9）d、胸闷缓解时间为（7.5±0.6）d，（P ＜0.05）。结论临床上采用孟鲁司特钠联合糖皮质激素治疗效果理想，值得推广使用。
目的：探討孟魯司特鈉聯閤糖皮質激素在中老年哮喘患者中的治療效果。方法對本院就診的80例中老年哮喘患者，根據不同治療方法分為兩組，對照組給予常規基礎治療及吸入糖皮質激素治療，實驗組在對照組基礎上聯閤孟魯司特鈉治療，比較兩組治療效果。結果實驗組95%患者的治療效果肯定，高于對照組（80%）（P ＜0.05）；實驗組治療後 FEV1指標為（2.22±0.18）L、PEF 指標為（4.89±0.48）L、FEV1/FVC指標為（88.54±5.62）%，高于對照組 FEV1指標為（1.45±0.29）L、PEF 指標為（3.51±0.47）L、FEV1/FVC指標為（77.13±6.43）%，（P ＜0.05）；實驗組喘息緩解時間為（5.3±0.6）d，咳嗽緩解時間為（6.5±0.8）d、胸悶緩解時間為（5.8±0.7）d，短于對照組喘息緩解時間為（7.8±0.3）d，咳嗽緩解時間為（8.6±0.9）d、胸悶緩解時間為（7.5±0.6）d，（P ＜0.05）。結論臨床上採用孟魯司特鈉聯閤糖皮質激素治療效果理想，值得推廣使用。
목적：탐토맹로사특납연합당피질격소재중노년효천환자중적치료효과。방법대본원취진적80례중노년효천환자，근거불동치료방법분위량조，대조조급여상규기출치료급흡입당피질격소치료，실험조재대조조기출상연합맹로사특납치료，비교량조치료효과。결과실험조95%환자적치료효과긍정，고우대조조（80%）（P ＜0.05）；실험조치료후 FEV1지표위（2.22±0.18）L、PEF 지표위（4.89±0.48）L、FEV1/FVC지표위（88.54±5.62）%，고우대조조 FEV1지표위（1.45±0.29）L、PEF 지표위（3.51±0.47）L、FEV1/FVC지표위（77.13±6.43）%，（P ＜0.05）；실험조천식완해시간위（5.3±0.6）d，해수완해시간위（6.5±0.8）d、흉민완해시간위（5.8±0.7）d，단우대조조천식완해시간위（7.8±0.3）d，해수완해시간위（8.6±0.9）d、흉민완해시간위（7.5±0.6）d，（P ＜0.05）。결론림상상채용맹로사특납연합당피질격소치료효과이상，치득추엄사용。
Objective To investigate the therapeutic effect of montelukast sodium combined with glucocorticoid in elderly patients of asthma. Methods 80 cases of elderly patients with asthma in our hospital were selected, according to the different treatment methods they were divided into two groups, the control group was given conventional basic therapy and inhaled corticosteroid treatment, the experimental group in the control group based on the combined with montelukast treatment, treatment effects were compared between the two groups. Results The experimental group of 95% patients with positive curative effect, higher than that of the control group (80%) (P < 0.05); the experimental group after treatment for FEV1 index (2.22±0.18) L, PEF index(4.89±0.48)L, FEV1/FVC index(88.54±5.62)%, higher than that of the control group(1.45 ±0.29) L, PEF index(3.51±0.47)L, FEV1/FVC index(77.13±6.43)%, (P < 0.05); the experimental group wheezing relief time was(5.3±0.6)days, cough relief time was(6.5±0.8)days, chest distress relief time was(5.8±0.7)days, it was shorter than that in the control group, asthmatic remission duration was(7.8±0.3) days, cough relief time was(8.6±0.9)days, chest distress relief time was(7.5±0.6)days,(P < 0.05). Conclusion Glucocorticoid combined with montelukast sodium on clinical uses has ideal effect, and it is worth to promote.
